We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04566445
Recruitment Status : Active, not recruiting
First Posted : September 28, 2020
Last Update Posted : December 16, 2022
Sponsor:
Collaborator:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Gyroscope Therapeutics Limited

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this clinical study is to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with geographic atrophy secondary to age-related macular degeneration (AMD).

Condition or disease Intervention/treatment Phase
Dry Age-related Macular Degeneration Drug: GT005: Medium Dose Drug: GT005: High Dose Phase 2

Detailed Description:

This is a Phase 2, open-label, outcomes-assessor masked, multicentre, randomised, controlled study to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with GA secondary to AMD.

The trial includes a screening period of up to 8 weeks and a 96-week study period.

Subjects will be randomised to one of two groups; GT005 or the untreated control group.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 255 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This is a Phase II, open-label, outcomes-assessor masked, multicentre, randomised, controlled study to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with GA secondary to AMD.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Quadruple (Participant, Care Provider, Investigator, Outcome Assessor). The overall objectives of the study are to evaluate the safety and efficacy (anatomical and functional visual outcomes) of two doses of GT005 in genetically defined subjects with GA due to AMD.
Primary Purpose: Treatment
Official Title: HORIZON: A Phase II, Open-label, Outcomes-assessor Masked, Multicentre, Randomised, Controlled Study to Evaluate the Safety and Efficacy of Two Doses of GT005 Administered as a Single Subretinal Injection in Subjects With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
Actual Study Start Date : September 28, 2020
Estimated Primary Completion Date : September 18, 2024
Estimated Study Completion Date : September 17, 2025

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: GT005 Medium Dose
Approximately 83 subjects are planned, with subjects randomised to GT005 Medium Dose.
 Drug: GT005: Medium Dose
The study will test two doses of GT005: Medium Dose and High Dose.
Experimental: GT005 High Dose
Approximately 83 subjects are planned, with subjects randomised to GT005 High Dose.
 Drug: GT005: High Dose
The study will test two doses of GT005: Medium Dose and High Dose.
No Intervention: Untreated control
Approximately 83 subjects are planned, with subjects randomised to untreated control.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Progression of geographic atrophy [ Time Frame: 72 weeks ]
    The change from baseline to Week 72 in GA area as measured by fundus autofluorescence (FAF)


Secondary Outcome Measures :
  1. Progression of geographic atrophy [ Time Frame: 96 weeks ]
    The change from baseline through Week 96 in GA area as measured by fundus autofluorescence (FAF)

  2. Evaluation of the safety and tolerability of GT005 [ Time Frame: 96 weeks ]
    Frequency of treatment emergent adverse events (AEs)

  3. Evaluation of the effect of GT005 on retinal anatomical measures [ Time Frame: 96 weeks ]
    Change in retinal morphology on multimodal imaging

  4. Evaluation of the effect of GT005 on functional measures [ Time Frame: 96 weeks ]
    Change in best corrected visual acuity (BCVA) Score via the early treatment for diabetic retinopathy (ETDRS) chart

  5. Evaluation of the effect of GT005 on functional measures [ Time Frame: 96 weeks ]
    Change in low luminance difference (LLD) via the ETDRS chart

  6. Evaluation of the effect of GT005 on visual function [ Time Frame: 96 weeks ]
    Change in reading performance as assessed by Minnesota low-vision reading test (MNRead) chart

  7. Evaluation of the effect of GT005 on visual function [ Time Frame: 96 weeks ]
    Change in functional reading independence (FRI) index

  8. Evaluation of the effect of GT005 on patient-reported outcomes [ Time Frame: 96 weeks ]
    Change in quality of life measured on the Visual Function Questionnaire-25 (VFQ-25)


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   55 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Able and willing to give written informed consent
  2. Age ≥55 years
  3. a. In Stage 1: Have a clinical diagnosis of GA secondary to AMD in the study eye, as determined by the Investigator, and a diagnosis of AMD in the contralateral eye; b. In Stage 2: Have a clinical diagnosis of GA secondary to AMD in the study eye, as determined by the Investigator, that is non-foveal, as determined by the central reading centre, or has a CFI rare variant genotype and meets inclusion criteria 3a, and a diagnosis of AMD in the contralateral eye (except if monocular)
  4. GA lesion(s) within an acceptable size on FAF, in the study eye
  5. The GA lesion in the study eye must reside completely within the FAF image
  6. Up to 25% of the enrolled study population are permitted to have CNV in the fellow eye
  7. Have a BCVA of ≥24 letters (6/95 or 20/320 Snellen acuity equivalent), using ETDRS charts, in the study eye
  8. a. In Stage 1: Meet one of the pre-specified AMD genetic subgroup criteria; b. In Stage 2: Genotyping is not required for study eligibility
  9. Able to attend all study visits and complete the study procedures
  10. Women of child-bearing potential must have a negative pregnancy test within 2 weeks prior to randomisation (not required for postmenopausal women) or provide documentation of being surgically sterilised

Exclusion Criteria:

  1. a. In Stage 1: Carriers of excluded genetic variants; b. In Stage 2: Subjects are excluded if they have a clinical diagnosis of Stargardt Disease or other retinal dystrophies
  2. Have a history, or evidence, of CNV in the study eye
  3. Presence of moderate/severe or worse non-proliferative, diabetic retinopathy in the study eye
  4. Have history of vitrectomy, sub-macular surgery, or macular photocoagulation in the study eye
  5. History of intraocular surgery in the study eye within 12 weeks prior to Visit 1
  6. Have clinically significant cataract that may require surgery during the study period in the study eye
  7. Presence of moderate to severe glaucomatous optic neuropathy, uncontrolled intraocular pressure (IOP), despite use of two or more topical agents; or a history of glaucoma-filtering or valve surgery
  8. Axial myopia of greater than -8 diopters in the study eye
  9. Have received any investigational product for the treatment of GA within the past 6 months or 5 half-lives (whichever is longer), other than nutritional supplements such as the age-related eye disease study (AREDS) formula
  10. Have received a gene or cell therapy at any time.
  11. Have a contraindication to the protocol specified corticosteroid regimen
  12. Are unwilling to use two forms of contraception (one of which being a barrier method) for 90 days post-dosing, if relevant
  13. Active malignancy within the past 12 months, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or prostate cancer with a stable prostate-specific antigen (PSA) ≥ 12 months
  14. Have any other significant ocular or non-ocular medical or psychiatric condition which, in the opinion of the Investigator, may either put the subject at risk or may influence the results of the study
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04566445


Locations
Show Show 62 study locations
Sponsors and Collaborators
Gyroscope Therapeutics Limited
Novartis Pharmaceuticals
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Gyroscope Therapeutics Limited
ClinicalTrials.gov Identifier: NCT04566445    
Other Study ID Numbers: GT005-03
First Posted: September 28, 2020    Key Record Dates
Last Update Posted: December 16, 2022
Last Verified: December 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Gyroscope Therapeutics Limited:
Dry age-related macular degeneration
Geographic atrophy
Retinal disease
 Eye disease
Retinal degeneration
Macular atrophy
Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Degeneration
Geographic Atrophy
Retinal Degeneration
Retinal Diseases
Eye Diseases